Trial Outcomes & Findings for Iodine I 131 Tositumomab or Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma (NCT NCT00416312)

Results Overview

tumor absorbed dose (Gy)

Recruitment status

COMPLETED

Target enrollment

9 participants

Primary outcome timeframe

up to 4 years

Results posted on

2018-08-27

All NHL patients treated by either Bexxar or Zevalin

Participant milestones
Measure	Conventional & Patient-specific Dosimetry Tumor absorbed dose calculations determined using both conventional dosimetry and 3D-RD patient-specific dosimetry software.
Overall Study STARTED	9
Overall Study Conventional Dosimetry	9
Overall Study Patient-specific Dosimetry	9
Overall Study COMPLETED	7
Overall Study NOT COMPLETED	2

Reasons for withdrawal
Measure	Conventional & Patient-specific Dosimetry Tumor absorbed dose calculations determined using both conventional dosimetry and 3D-RD patient-specific dosimetry software.
Overall Study tumors not visible on imaging	2

Tumors could not be detected on imaging for 2 of the 9 enrolled patients

Baseline characteristics by cohort
Measure	Conventional & Patient-specific Dosimetry n=9 Participants Tumor absorbed dose calculations determined using both conventional dosimetry and 3D-RD patient-specific dosimetry software.
Age, Categorical <=18 years	0 Participants n=7 Participants • Tumors could not be detected on imaging for 2 of the 9 enrolled patients
Age, Categorical Between 18 and 65 years	1 Participants n=7 Participants • Tumors could not be detected on imaging for 2 of the 9 enrolled patients
Age, Categorical >=65 years	6 Participants n=7 Participants • Tumors could not be detected on imaging for 2 of the 9 enrolled patients
Sex: Female, Male Female	1 Participants n=7 Participants • Tumors could not be detected on imaging for 2 of the 9 enrolled patients
Sex: Female, Male Male	6 Participants n=7 Participants • Tumors could not be detected on imaging for 2 of the 9 enrolled patients

Timeframe: up to 4 years

tumor absorbed dose (Gy)

Outcome measures
Measure	Conventional & Patient-specific Dosimetry n=7 tumor Tumor absorbed dose calculations determined using both conventional dosimetry and 3D-RD patient-specific dosimetry software.
Tumor Absorbed Dose Conventional dosimetry	3.01 Gy Standard Deviation 3.04
Tumor Absorbed Dose Patient-specific dosimetry	3.41 Gy Standard Deviation 3.1

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Adverse event data not reported

Adverse event data not reported

Johns Hopkins University, School of Medicine

Phone: 410 614 0116